SDAT-IRC Study

Project objectives

“Single versus Dual Antiplatelet Therapy in patients with Incomplete Revascularization after Coronary artery bypass graft surgery” (SDAT-IRC study). Trial registration: ClinicalTrials.gov identifier NCT03789916. The study (randomized clinical trial) aims to evaluate the effectiveness of double antiplatelet therapy (with acetylsalicylic acid and ticagrelor) compared to single antiplatelet therapy with acetylsalicylic acid in patients undergoing coronary artery bypass grafting, with incomplete myocardial revascularization. Patients are included in which the intraoperative evaluation defines that it is not possible to carry out an anatomically complete myocardial revascularization (due to diffusely calcified coronary lesions or small caliber epicardial vessels or extended intra-myocardial course), not candidates for subsequent percutaneous completion procedures, and without recent acute coronary syndrome. The primary endpoint of the study is the evaluation of cardiac mortality, and will be conclusively evaluated 5 years after hospital discharge. Secondary endpoints include major adverse cardiac and cerebrovascular events (MACCEs): cardiac mortality, myocardial infarction, revascularization procedure on an already treated vessel ("repeated vessel revascularization”), hospitalization for heart failure, major cardiac arrhythmias, stroke.

Start and end date

Project Manager

Coordinating institution of the project